Complementary mAb Polishing Solutions for Viral Clearance and Aggregate Removal - Register Now!
|Articles|June 1, 2018

Alcami Announces Deal with New Investors

Madison Dearborn Partners will acquire a majority ownership position in CDMO Alcami.

Alcami Corporation announced in a June 1, 2018 press statement that Madison Dearborn Partners, LLC (MDP), a private equity firm based in Chicago, will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation.

The Durham, NC-based contract development and manufacturing firm has 10 locations worldwide and provides API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, drug product manufacturing, and packaging and stability services tailored to small and mid-size pharmaceutical and biotechnology companies.

The current Alcami's management team, led by Chief Executive Officer, President, and Chairman, Stephan Kutzer, will continue with the company. The company expects the transaction to be completed in the third quarter of 2018, pending customary closing conditions.

"The entire Alcami team is excited to further enhance and evolve the small to mid-size pharma growth engine. As we enter our next stage of progress as a leading global, clinically-focused and fully-integrated contract development and manufacturing organization, we are proud to partner with MDP to expand our talented employee base and further develop our capabilities," said Kutzer in the press release.

Source: Alcami

 


Related to this article

Stainless steel bioreactor vessels in a manufacturing facility. | Image Credit: © Corona Borealis - stock.adobe.com
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.